Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neobella is an injectable lipolytic solution primarily composed of synthetic deoxycholic acid, a bile acid that naturally occurs in the human body to facilitate the breakdown and absorption of dietary fat. It is specifically designed for non-surgical fat reduction and body contouring, particularly for the treatment of submental fullness (double chin) and localized fat deposits in areas such as the abdomen, thighs, and arms. Although sometimes categorized alongside dermal fillers in aesthetic product catalogs, Neobella is not a volumizing agent; instead, it acts as a cytolytic drug that disrupts the phospholipid bilayer of adipocyte (fat cell) membranes. This process, known as adipocytolysis, leads to the permanent destruction of fat cells, which are then naturally metabolized and cleared by the body's lymphatic system. Developed by New-Bio in South Korea, Neobella was distributed in the United States by Vivid Scientific prior to the distributor's closure.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Neobella.